Enhancement of ricin toxin A chain immunotoxin activity: Synthesis, ionophoretic ability, and in vitro activity of monensin derivatives

Biochemical Pharmacology

Volumn 52, Issue 1, 1996, Pages 157-166

  Dosio, Franco ^a   Franceschi, Antonia ^b   Ceruti, Maurizio ^a   Brusa, Paola ^a   Cattel, Luigi ^a   Colombatti, Marco ^b  

^a Ist di Chim Farmaceut Applicata   (Italy)

^b POLICLINICO BORGO ROMA   (Italy)

Author keywords

drug targeting; enhancer; immunotoxin; monensin; ricin A chain

Indexed keywords

IMMUNOTOXIN; MONENSIN; MONENSIN CILIATINE AMIDE; MONENSIN DERIVATIVE; MONENSIN DIMETHYLAMINOETHYLAMIDE; MONENSIN METHYL ESTER; MONENSIN SQUALANE AMIDE; MONENSIN SQUALENE AMIDE; MONENSIN TAURINE AMIDE; MONENSIN TYRAMIDE; MONOCLONAL ANTIBODY; PROTEIN SUBUNIT; RICIN A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IONTOPHORESIS; LEUKEMIA CELL LINE; LIPOPHILICITY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

EID: 0029924927     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00176-1     Document Type: Article

References (48)

1. Pietersz GA and McKenzie JFC, Antibody conjugates for the treatment of cancer. Immunol Rev 127: 57-80, 1992.
2. Candiani C, Franceschi A, Chignola C, Pasti M, Anselmi C, Benoni G, Tridente G and Colombatti M, Blocking effect of human serum but not of cerebrospinal fluid on ricin A chain immunotoxin potentiation by monensin or carrier protein-monensin conjugates. Cancer Res 52: 623-630, 1992.
3. Jansen FK, Blythman HE, Casellas P, Derocq JM and Dussossoy D, Enhancement of ITs: in vitro and in vivo. In: Membrane-mediated cytotoxicity (Eds. Bonavida B, Collier RJ), vol 45, pp. 167-173. Alan R. Liss Inc., New York, 1987.
4. Hara H and Seon BK, Complete suppression of in vivo growth of human leukemia cells by specific immunotoxin: nude mouse model. Proc Natl Acad Sci USA 84: 3390-3394, 1987.
5. Griffin TW, Richardson C, Houston LL, LePage D, Bogden A and Raso V, Antitumor activity of intraperitoneal immunotoxin in a nude mouse model of human malignant mesothelioma. Cancer Res 47: 4266-4270, 1987.
6. Griffin TW, Morgan AC and Blythman HE, Immunotoxin therapy assessment by animal models. In: Immunotoxins (Ed. Frankel AE), pp. 433-455. Kluwer Academic Publishers, Boston, 1988.
7. Hara H, Luo Y, Haruta Y and Seon BK, Efficient transplantation of human non-T leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A chain conjugates of monoclonal antibody. Cancer Res 48: 4673-4680, 1988.
8. Laurent G, Pris J, Farcet JP, Carayon P, Blythman H, Casellas P, Poncelet P and Jansen FK, Effects of therapy with T101-ricin A chain immunotoxin in two leukemic patients. Blood 67: 1680-1687, 1986.
9. Spitler LE, Del Rio M, Khentigan A, Wedel NI, Brophy NA, Miller LL, Harkonen WS, Rosendorf LL, Lee HM, Mischak RP, Kawahata RT, Stoudemire JB, Fradkin LB, Bautista EE and Scannon PJ, Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res 47: 1717-1723, 1987.
10. Weiner FM, O'Dwyer J, Kitson J, Comis RL, Frankel AE, Bauer RJ, Konrad MS and Groves ES, Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res 47: 4062-4067, 1989.
11. Byers VS, Rodvien R, Grant K, Durrant LG, Hudson KH, Baldwin RW and Scannon PJ, Phase I study of monoclonal antibody-ricin A chain immunotoxin Xomazyme 791 in patients with metastatic colon cancer. Cancer Res 49: 6153-6160, 1989.
12. Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr JW and Thorpe PE, Phase I trial in patients with B cell lymphoma. Cancer Res 51: 4052-4058, 1991.
13. LeMaistre CF, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, Drajesk J, Fishwild D, Scannon P and Byers V, Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 78: 1173-1182, 1991.
14. Ravel S, Colombatti M and Casellas P, Internalization and intracellular fate of anti-CD5 monoclonal antibody and anti-CD5-ricin A chain immunotoxin in human leukemic T cells. Blood 79: 1511-1517, 1992.
15. Wargalla UC and Reisfeld RA, Rate of internalization of an immunotoxin correlates with cytotoxic activity against tumor cells. Proc Natl Acad Sci USA 86: 5146-5150, 1989.
16. 2- (ricin A chain) immunotoxin into human T-leukemic cells. Eur J Biochem 192: 469-473, 1990.
17. Press OW, Vitetta ES, Farr AG, Hansen JA and Martin PJ, Evaluation of ricin A-chain immunotoxin directed against human T cells. Cell Immunol 102: 10-20, 1986.
18. Youle RJ and Neville DM, Role of endocytous and receptor recycling in ligand-toxin and antibody-toxin conjugate activity. In: Immunoconjugates, Antibody conjugates in radioimaging and therapy of cancer (Ed. Vogel C), pp. 153-169, Oxford University Press, New York, 1987.
19. Calafat J, Molthoff C, Janssen H and Hilkens J, Endocytosis and intracellular routing of an antibody-ricin A chain conjugate. Cancer Res 48: 3822-3827, 1988.
20. Byers VS, Pawluczyk ZA, Hooi DSW, Price MR, Carrol S, Embleton MJ, Garnett MC, Berry N, Robin RA and Baldwin RW, Endocytosis of immunotoxin 79IT/36-RTA by tumor cells in relation to its cytotoxic action. Cancer Res 51: 1990-1995, 1991.
21. Hwang KM, Foon KA, Cheung PH, Pearson JW and Olham RK, Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen. Cancer Res 44: 4578-4586, 1984.
22. Pirker R, FitzGerald D, Hamilton T, Ozols R, Laird W, Frankel A, Willingham M and Pastan I, Characterization of immunotoxins active against ovarian cancer cell lines. J Clin Invest 76: 1261-1267, 1985.
23. Henderson PJF, McGivan D and Chappel JB, Action of certain antibodies on mitochondrial, erythrocyte and artificial phospholipid membranes. Role of induced proton permeability. Biochem J 111: 521-524, 1969.
24. Shavit N, Degani H and SanPietro A, Effects of ionophores antibiotics in chloroplasts. Biochim Biophys Acta 216: 208-211, 1970.
25. Casellas P, Bourrie JP, Gros P and Jansen FK, Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores. J Biol Chem 259: 9359-9364, 1984.
26. Ramakrishnan S and Houston LL, Inhibition of human acute lymphoblastic leukemia cells by immunotoxin: potentiation by chloroquine. Science 223: 58-61, 1984.
27. Colombatti M, Dell'Arciprete L, Chignola R and Tridente G, Carrier protein-monensin conjugates: enhancement of immunotoxin cytotoxicity and potential in tumor treatment. Cancer Res 50: 1385-1391, 1990.
28. Mollenhauer HH, Morrè DJ and Rowe LD, Alteration of intracellular traffic by monensin: mechanism, specificity and relationship to toxicity. Biochim Biophys Acta 1031: 225-246, 1990.
29. Jansen FK, Jansen A, Derocq JM, Carriere D, Carayon P, Veas F and Jaffrezou JP, Golgi vacuolization and immunotoxin enhancement by monensin and perhexilin depend on a serum protein. J Biol Chem 267: 12577-12582, 1992.
30. Franceschi A, Dosio F, Anselmi C, Chignola R, Candiani C, Pasti M, Tridente G and Colombatti M, Mechanisms involved in serum-dependent inactivation of the immunotoxin enhances monensin and carrier-protein-monensin. Eur J Biochem 219: 469-479, 1994.
31. Tartakoff AM, Perturbation of vesicular traffic with carboxylic ionophore monensin. Cell 32: 1026-1028, 1983.
32. Brown MS, Anderson RGW and Goldstein JL, Recycling receptors: the round-trip itinerary of migrant membrane proteins. Cell 32: 663-667, 1983.
33. Raso V and Lawrence J, Carboxylic ionophores enhance the cytotoxic potency of ligand and antibody-delivered ricin A chain. J Exp Med 160: 1234-1240, 1984.
34. Tohda K, Suzuki K, Kosuge N, Watanabe K, Nagashima H, Inoue H and Shirai T, Design and synthesis of lithium ionophores for an ion-selective electrode by chemical modification of natural carboxylic polyether antibiotic monensin. Anal Chem 62: 936-942, 1990.
35. Biagi GL, Guerra MC and Barbaro AM, Relationship between lipophilic character and hemolitic activity of testosterone esters. J Med Chem 13: 944-948, 1970.
36. Biagi GL, Barbaro AM and Guerra MC, Partition data of cephalosporins determined by means of reversal-phase thin-layer chromatography. J Chromat 44: 195-198, 1969.
37. Antin JH, Bierer BE, Smith BR, Guinan EC, Provost MM, Ferrara J, Macklis R, Tarbell NJ, Blythman H, Bouloux C, Zinniti LM, Bogart RE, Burakoff S and Weinstein H, Depletion of bone marrow T-lymphocytes with an anti CD5 anti-body (ST-1 IT): effective prophylaxes for graft-versus-host disease. Prog Clin Biol Res 333: 207-216, 1990.
38. Colombatti M, Bisconti M, Dell'Arciprete L, Gerosa M and Tridente G, Sensitivity of human glioma cells to cytotoxic heteroconjugates. Int J Cancer 42: 441-448, 1988.
39. Klausner RD, van Renswoude J, Ashwell G, Kempf C, Schechter AN, Dean A and Bridges KR, Receptor-mediated endocytosis of transferrin in K562 cells. J Biol Chem 258: 4715-4724, 1983.
40. Ohkuma S and Poole B, Fluorescence probe measurement of the intralysosomal pH in lung cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 73: 3327-3331, 1978.
41. Chignola R, Colombatti M, Dell'Arciprete L, Candiani C and Tridente G, Distribution of endocytosed molecules to intracellular acidic environments correlates with immunotoxin activity, Int J Cancer 46: 1117-1123, 1990.
42. Hertler AA, Frankel AE, Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol 7: 1932-1935, 1989.
43. Uckun FM and Frankel AE, The current status of immunotoxins: an overview of experimental and clinical studies as presented at the Third International Symposium on immunotoxins. Leukemia 7: 341-345, 1993.
44. Griffin TW, Childs LR, FitzGerald DJP and Levin LV, Enhancement of the cytotoxic effect of anti-carcinoembrionic antigen immunotoxin by adenovirus and carboxylic ionophores. J Natl Cancer Inst 79: 679-685, 1987.
45. Carriere D, Casellas P, Richer G, Gros P, Jansen FK, Endocytosis of an antibody ricin A-chain conjugate (immuno-A-toxin) adsorbed on colloidal gold. Effects of ammonium chloride and monensin. Exp Cell Res 156: 327-340, 1985.
46. Dautry-Varsat A, Ciechanover A, Lodish HF, pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci USA 80: 2250-2262, 1983.
47. Nakamura A, Nagai S, Takahashi T, Malhan R, Murakami N, Ueda T, Sakakibara J and Asano M, Studies on the chemical modification of monensin IV. Synthesis, sodium ionpermeability and biological activity of 7-O-acyl and 7-O-alkyl monensins. Chem Pharm Bull 40: 2331-2337, 1992.
48. Sandvig K, Olsnes S and Pihl A, Inhibitory effect of ammonium chloride and chloroquine on the entry of the toxic lectin moddecin into HeLa cells. Biochem Biophys Res Comm 90: 648-655, 1979.